• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Latest News
    • Cardiovascular
    • Orthopedics
  • Wall Street Beat
    • Funding Roundup
    • Mergers & Acquisitions
  • Podcasts & Webinars
    • Podcasts
    • Webinars
  • Resources
    • About MassDevice
    • Newsletter Signup
    • Leadership in Medtech
    • Manufacturers & Suppliers Search
    • MedTech 100 Index
    • Videos
    • Whitepapers
  • DeviceTalks Tuesdays
  • Coronavirus: Live updates
Home » Anti-Essure movement grows online as women slam Bayer’s implant | MassDevice.com On Call

Anti-Essure movement grows online as women slam Bayer’s implant | MassDevice.com On Call

November 13, 2013 By Arezu Sarvestani

MassDevice On Call

MASSDEVICE ON CALL — The anti-Essure movement, launched by women who claim the permanent contraceptive implant left them with severe pain and injuries, doesn’t look likely to die down, having spawned Facebook support pages, Twitter campaigns and lots of media attention.

The movement has attached itself to the Twitter hashtag ‘#EssureRally’, through which women are calling on Bayer to recall the device, posting pictures of the ralliers in action and organizing real-world events, including street-corner picketing and conference calls with famed consumer advocate Erin Brockovich.

The story has even driven passionate reactions here on MassDevice.com, where ralliers have called on Bayer to release its full clinical study reports and chided the FDA for failing to issue a recall on the device.

The FDA late last month commented on the growing anti-Essure movement, saying that real-world results don’t support reports of extreme fatigue, depression, weight-gain and other issues associated with the implant. The FDA said that it reviewed adverse event and complications reports, 5-year post-approval study results and clinical literature on Essure, concluding that there was no reason to believe that the device was connected to new complaints.

The agency added that Essure is 99.83% effective as a means of permanent sterilization, and that rare cases of sterilization failure, as well as certain post-treatment problems, are known issues listed in the product’s labeling.

Anti-Essure ralliers challenged the 5-year study, saying the results have been under wraps for too long and that their conclusions are inevitably biased, having been reported by "manufacturer paid consultants," according to one commenter.

The movement also took issue with medical device industry analyst Joseph Gregory, who came out against Brockovich’s recent interest in Essure, saying that the device helps thousands and bears a less-than-1% apparent major adverse event rate.

"While the reported adverse cases are very serious and represent potential issues with the Essure device, or the procedure itself, they have to be considered in reference to how many patients in total have utilized and benefited from this procedure," Gregory said in an official statement sent to MassDevice.com. "Although the adverse event profile may seem immensely large when highlighted, it isn’t large enough to surpass 1%."

"This doesn’t mean that Ms. Brockovich should stop being a resource for women who are interested in undergoing the procedure, or who have a medical story to share," he added. "However, her resources would be better directed to where the evidence supports her argument."

Brockovich, the activist made famous by Julia Roberts’ portrayal in a 2000 blockbuster film, announced last month that she was taking an interest in Bayer and the Essure device after her organization was inundated with hundreds of inquiries from women who claimed the device had left them with serous issues. The reports included chronic pain, including colon perforations caused by movement of the device, implants that have been lost and are no longer visible on scans, pregnancies despite the presence of the implants and debilitating headaches, according to Brockovich’s website.

Essure is a permanent form of birth control, comprised of flexible inserts that are implanted in the fallopian tubes where scar tissue forms around them to prevent fertilization. The procedure is incision-free, is done on an outpatient basis and takes all of 10 minutes to perform, according to Bayer’s online materials.

Essure is part of the product portfolio that Bayer acquired in the $1.1 billion buyout of Conceptus (NSDQ:CPTS), which the companies announced earlier this year. Conceptus won FDA approval for Essure in 2002.

 Abbott Labs joins forces with techno music titan Tiesto
Healthcare giant Abbott and legendary DJ Tiesto teamed up to promote blood donation among young adults. The Music Saves Lives initiative is offering winners a chance to meet Tiesto, attend concerts and access media if they participate in local blood drives.
Read more

 Problems persist for asthma, diabetes apps
Patients and healthcare providers are eager to adopt clinical apps that help manage care for asthmatics and diabetics, but there are still a few kinks to work out, including lack of data on patient outcomes, issues integrating apps with electronic health record systems and concerns about privacy and security.
Read more

 Boston’s Caliber I.D. channels Star Trek with real-world medical ‘tricorder’
Massachusetts-based Caliber Imaging & Diagnostics says its FDA-cleared VivaScope confocal, inspired by the medical tricorders used in the Star Trek television and movie series, can non-invasively provide imaging that can help diagnose skin cancer and other skin-related diseases.
Read more

 TransMedics’ organ transport system keeps the heart beating
Andover, Mass.-based organ-transport system maker TransMedics demonstrated with a pig’s heart how its Organ Care System uses electrodes and warm blood to keep the heart fresh and pumping, rather than on ice, in preparation for transplant.
Read more

Filed Under: News Well, Recalls, Women's Health Tagged With: Bayer, Conceptus Inc., On Call, Patient Safety, Personal Injury

In case you missed it

  • Report: Dexcom in talks to acquire Insulet
  • Henry Schein investors push back on executive pay
  • Alcon to pay $60M to acquire Kala Pharmaceuticals’ dry eye treatment
  • Creo Medical inks collaboration agreement with Intuitive
  • MedTrace Pharma moves forward on 15 O-water imaging tech
  • HistoSonics, GE Healthcare agree to integrate ultrasound into sonic beam liver therapy
  • Pfizer, BioNTech moving forward on seeking COVID-19 vaccine EUA for youngest children
  • Zimmer Biomet narrowly avoids shareholder rebuke on executive pay
  • FDA says Philips ventilator recall produced over 21,000 device reports, 124 deaths
  • Boston Scientific’s Acurate Neo2 valve performs well in studies
  • MicroTransponder reports first commercial implantation of its stroke rehab neurostim system
  • Ambu replaces CEO with new leadership
  • Moderna’s first bivalent COVID-19 vaccine booster candidate shows promise
  • AdvaMed joins Biden’s Joint Supply Chain Resilience Working Group
  • FDA clears Accelus’ Toro-L interbody fusion system
  • Teleflex’s UroLift cleared in China to treat BPH
  • Globus Medical announces first surgeries with Excelsius3D

RSS From Medical Design & Outsourcing

  • Henry Schein investors push back on executive pay
    Nearly half of Henry Schein (Nasdaq:HSIC) shareholders who voted at this month’s annual meeting voted against the company’s pay packages for top executives, according to a new SEC filing. About 48.5% of voting shareholders voted against the company’s executive pay plan in what’s known as the Say-on-Pay vote, according to vote results of the May… […]
  • Creo Medical inks collaboration agreement with Intuitive
    Creo Medical Group (LON: CREO) announced today that it has signed a multi-year collaboration agreement with Intuitive to make certain Creo surgical technologies compatible with the surgical robotic giant’s systems. The London exchange reacted by sending CREO shares up more than 4% to 100 pence apiece by the close of trading today. As of midday… […]
  • MedTrace Pharma moves forward on 15 O-water imaging tech
    MedTrace Pharma announced the first person scanned in its Rapid-Water-Flow Phase 3 clinical trial, further testing its tech to bring 15 O-water to imaging. The first subject scan took place at Aarhus University Hospital in Denmark, using 15 O-water produced, dosed and injected through MedTrace’s P3 automated delivery system. The clinical trial aims to evaluate… […]
  • Zimmer Biomet narrowly avoids shareholder rebuke on executive pay
    An unusually large share of Zimmer Biomet (NYSE:ZBH) investors voted against the orthopedics company’s pay packages for top executives at the annual shareholder meeting. About 54% of voting shareholders supported the pay packages of the company’s five top-paid executives at the May 13 meeting, according to results filed with the SEC yesterday. In 2021, nearly 93%… […]
  • BD, Mitsubishi Gas Chemical partner on better materials for plastic syringes
    BD (NYSE:BDX) announced that it partnered with Mitsubishi Gas Chemical Company on applying new technology to pre-fillable syringes. MGC develops the Oxycapt technology designed to integrate the best of plastic and glass for plastic syringes. BD and Tokyo-based MGC will work together to apply Oxycapt technology to the next generation of pre-fillable syringes (PFS) for advanced… […]
  • Ambu replaces CEO with new leadership
    Ambu today said it has hired board member Britt Meelby Jensen to replace CEO Juan Jose Gonzalez, effective tomorrow. “Since Juan Jose Gonzalez joined as CEO in 2019, Ambu has made good progress and achieved important milestones on the strategic transformation into the world’s largest single-use endoscopy company,” Ambu Chair Jørgen Jensen said in a… […]
  • AdvaMed joins Biden’s Joint Supply Chain Resilience Working Group
    AdvaMed executive Abby Pratt has joined the executive committee for the Biden administration’s Joint Supply Chain Resilience Working Group, the medtech industry association said today. The working group’s members from government and industry will assist with implementation of the National Strategy for a Resilient Public Health Supply Chain. Pratt oversees supply chain issues as SVP… […]
  • Toray develops new stretchable film for medical devices
    Toray Industries has a new stretchable film based on its proprietary polymer Reactis technology, with potential applications that include robotics and biological and industrial sensors. Tokyo-based Toray said it shipped samples to customers and plans research and development efforts to commercialize the new grade of film. “Recent years have increased the potential for developing stretchable… […]
  • Google Health hires FDA’s chief digital health officer
    Former FDA Chief Digital Health Officer of Global Strategy and Innovation Bakul Patel has started a new job with Google after 13 years with the regulatory agency. Patel became senior director, global digital health strategy and regulatory for Google Health earlier this month, he said on LinkedIn. Patel recounted highlights of his “incredible journey since… […]
  • Expect more heart and lung failure years after COVID, Abbott’s heart failure CMO says
    Two years into the COVID-19 pandemic, we know more than ever about the SARS-CoV-2 virus and how quickly it moves to ravage the human body. What remains to be seen is how the virus — and perhaps more importantly, our immune system’s response to it — will affect the health of people long after infection,… […]
  • FDA moves forward with Voluntary Improvement Program to bolster medical device quality
    Kathryn Burke, Emergo Group The U.S. Food and Drug Administration has issued new draft guidance to establish a full-blown voluntary program for improving quality-related processes in medical device manufacturing following promising results of a pilot program. The FDA guidance stems from a pilot undertaken by the agency along with the Medical Device Innovation Consortium (MDIC) in 2018.… […]

Leave a Reply

You must be logged in to post a comment.

Primary Sidebar

DeviceTalks Weekly

May 20, 2022
DeviceTalks Boston Post-Game – Editors’ Top Moments, Insulet’s Eric Benjamin on future of Omnipod 5
See More >

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Need Medtech news in a minute?
We Deliver!

MassDevice Enewsletters get you caught up on all the mission critical news you need in med tech. Sign up today.

MDO ad

Footer

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion
Drug Discovery & Development
Pharmaceutical Processing World
MedTech 100 Index
R&D World

Device Talks Webinars, Podcasts, & Discussions

Attend our Monthly Webinars
Listen to our Weekly Podcasts
Join our Device Talks Tuesdays Discussion

MASSDEVICE

Subscribe to MassDevice E-Newsletter
Advertise with us
About
Contact us
Add us on Facebook Follow us on Twitter Connect with us on LinkedIn Follow us on YouTube

Copyright © 2022 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Advertise | Privacy Policy | RSS